Induction of macrophage chemotaxis by aortic extracts from patients with marfan syndrome is related to elastin binding protein

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Guo, Gao ^a   Gehle, Petra ^a,b   Doelken, Sandra ^a,c   Martin Ventura, José Luis ^d   von Kodolitsch, Yskert ^e   Hetzer, Roland ^a,b   Robinson, Peter N ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^c MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; ELASTIN BINDING PROTEIN; HEXAPEPTIDE; LACTOSE; UNCLASSIFIED DRUG; ELASTIN; MONOCLONAL ANTIBODY; TISSUE EXTRACT;

ADULT; AGED; ANIMAL CELL; AORTA; AORTA ANEURYSM; ARTICLE; ASCENDING AORTA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MACROPHAGE MIGRATION; MALE; MARFAN SYNDROME; MOUSE; NONHUMAN; THORACIC AORTA ANEURYSM; ANIMAL; CATTLE; CHEMOTAXIS; CYTOLOGY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; MACROPHAGE; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; AORTA; AORTIC ANEURYSM, THORACIC; CATTLE; CHEMOTAXIS; ELASTIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MACROPHAGES; MALE; MARFAN SYNDROME; MICE; MIDDLE AGED; TISSUE EXTRACTS; YOUNG ADULT;

EID: 79957613541     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020138     Document Type: Article

References (61)

1. von Kodolitsch Y, Robinson PN, (2007) Marfan syndrome: an update of genetics, medical and surgical management. Heart 93: 755-760.
2. von Kodolitsch Y, Rybczynski M, Bernhardt A, Mir TS, Treede H, et al. (2010) Marfan syndrome and the evolving spectrum of heritable thoracic aortic disease: do we need genetics for clinical decisions? Vasa 39: 17-32.
3. Robinson PN, Arteaga-Solis E, Baldock C, Collod-Broud G, Booms P, et al. (2006) The molecular genetics of Marfan syndrome and related disorders. J Med Genet 43: 769-787.
4. Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, et al. (2003) Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 278: 2750-2757.
5. Ramirez F, Sakai LY, (2010) Biogenesis and function of fibrillin assemblies. Cell Tissue Res 339: 71-82.
6. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, et al. (2003) Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33: 407-411.
7. Ng CM, Cheng A, Myers LA, Martinez-Murillo F, Jie C, et al. (2004) TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 114: 1586-1592.
8. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, et al. (2006) Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of marfan syndrome. Science 312: 117-121.
9. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, et al. (2007) Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13: 204-210.
10. Judge DP, Biery NJ, Keene DR, Geubtner J, Myers L, et al. (2004) Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest 114: 172-181.
11. Mátyás G, Alonso S, Patrignani A, Marti M, Arnold E, et al. (2007) Large genomic fibrillin-1 (FBN1) gene deletions provide evidence for true haploinsufficiency in Marfan syndrome. Hum Genet 122: 23-32.
12. Chung AWY, Yeung KA, Cortes SF, Sandor GGS, Judge DP, et al. (2007) Endothelial dysfunction and compromised eNOS/Akt signaling in the thoracic aorta during the progression of Marfan syndrome. Br J Pharmacol 150: 1075-1083.
13. Chung AWY, Yang HHC, van Breemen C, (2007) Imbalanced synthesis of cyclooxygenase-derived thromboxane A2 and prostacyclin compromises vasomotor function of the thoracic aorta in Marfan syndrome. Br J Pharmacol 152: 305-312.
14. Yang HHC, van Breemen C, Chung AWY, (2010) Vasomotor dysfunction in the thoracic aorta of Marfan syndrome is associated with accumulation of oxidative stress. Vascul Pharmacol 52: 37-45.
15. Aoyama T, Francke U, Dietz HC, Furthmayr H, (1994) Quantitative differences in biosynthesis and extracellular deposition of fibrillin in cultured fibroblasts distinguish five groups of Marfan syndrome patients and suggest distinct pathogenetic mechanisms. J Clin Invest 94: 130-137.
16. Milewicz DM, Grossfield J, Cao SN, Kielty C, Covitz W, et al. (1995) A mutation in FBN1 disrupts profibrillin processing and results in isolated skeletal features of the Marfan syndrome. J Clin Invest 95: 2373-2378.
17. Booms P, Tiecke F, Rosenberg T, Hagemeier C, Robinson PN, (2000) Differential effect of FBN1 mutations on in vitro proteolysis of recombinant fibrillin-1 fragments. Hum Genet 107: 216-224.
18. Reinhardt DP, Ono RN, Notbohm H, Mller PK, Bchinger HP, et al. (2000) Mutations in calcium-binding epidermal growth factor modules render fibrillin-1 susceptible to proteolysis. a potential disease-causing mechanism in Marfan syndrome. J Biol Chem 275: 12339-12345.
19. McGettrick AJ, Knott V, Willis A, Handford PA, (2000) Molecular effects of calcium binding mutations in Marfan syndrome depend on domain context. Hum Mol Genet 9: 1987-1994.
20. Robinson PN, Booms P, (2001) The molecular pathogenesis of the Marfan syndrome. Cell Mol Life Sci 58: 1698-1707.
21. Whiteman P, Smallridge RS, Knott V, Cordle JJ, Downing AK, et al. (2001) A G1127S change in calcium-binding epidermal growth factor-like domain 13 of human fibrillin-1 causes short range conformational effects. J Biol Chem 276: 17156-17162.
22. Suk JY, Jensen S, McGettrick A, Willis AC, Whiteman P, et al. (2004) Structural consequences of cysteine substitutions C1977Y and C1977R in calcium-binding epidermal growth factor-like domain 30 of human fibrillin-1. J Biol Chem 279: 51258-51265.
23. Vollbrandt T, Tiedemann K, El-Hallous E, Lin G, Brinckmann J, et al. (2004) Consequences of cysteine mutations in calcium-binding epidermal growth factor modules of fibrillin-1. J Biol Chem 279: 32924-32931.
24. Robinson PN, Booms P, Katzke S, Ladewig M, Neumann L, et al. (2002) Mutations of FBN1 and genotype-phenotype correlations in Marfan syndrome and related fibrillinopathies. Hum Mutat 20: 153-161.
25. Downing AK, Knott V, Werner JM, Cardy CM, Campbell ID, et al. (1996) Solution structure of a pair of calcium-binding epidermal growth factor-like domains: implications for the marfan syndrome and other genetic disorders. Cell 85: 597-605.
26. Whiteman P, Downing AK, Smallridge R, Winship PR, Handford PA, (1998) A Gly -> Ser change causes defective folding in vitro of calcium-binding epidermal growth factor-like domains from factor IX and fibrillin-1. J Biol Chem 273: 7807-7813.
27. Fleischer KJ, Nousari HC, Anhalt GJ, Stone CD, Laschinger JC, (1997) Immunohistochemical abnormalities of fibrillin in cardiovascular tissues in Marfan's syndrome. Ann Thorac Surg 63: 1012-1017.
28. Pilop C, Aregger F, Gorman RC, Brunisholz R, Gerrits B, et al. (2009) Proteomic analysis in aortic media of patients with Marfan syndrome reveals increased activity of calpain 2 in aortic aneurysms. Circulation 120: 983-991.
29. Segura AM, Luna RE, Horiba K, Stetler-Stevenson WG, McAllister HA, et al. (1998) Immuno-histochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan's syndrome. Circulation 98: II331-7; discussion II337-8.
30. Ikonomidis JS, Jones JA, Barbour JR, Stroud RE, Clark LL, et al. (2006) Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation 114: I365-I370.
31. Chung AWY, Yeung KA, Sandor GGS, Judge DP, Dietz HC, et al. (2007) Loss of elastic fiber integrity and reduction of vascular smooth muscle contraction resulting from the upregulated activities of matrix metalloproteinase-2 and-9 in the thoracic aortic aneurysm in Marfan syndrome. Circ Res 101: 512-522.
32. Chung AWY, Yang HHC, Radomski MW, van Breemen C, (2008) Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and-9. Circ Res 102: e73-e85.
33. Xiong W, Knispel RA, Dietz HC, Ramirez F, Baxter BT, (2008) Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome. J Vasc Surg 47: 166-72; discussion 172.
34. Pfaff M, Reinhardt DP, Sakai LY, Timpl R, (1996) Cell adhesion and integrin binding to recombinant human fibrillin-1. FEBS Lett 384: 247-250.
35. D'Arrigo C, Burl S, Withers AP, Dobson H, Black C, et al. (1998) TGF-beta1 binding protein-like modules of fibrillin-1 and-2 mediate integrin-dependent cell adhesion. Connect Tissue Res 37: 29-51.
36. Bax DV, Bernard SE, Lomas A, Morgan A, Humphries J, et al. (2003) Cell adhesion to fibrillin-1 molecules and microfibrils is mediated by alpha 5 beta 1 and alpha v beta 3 integrins. J Biol Chem 278: 34605-34616.
37. McGowan SE, Holmes AJ, Mecham RP, Ritty TM, (2008) Arg-Gly-Asp-containing domains of fibrillins-1 and-2 distinctly regulate lung fibroblast migration. Am J Respir Cell Mol Biol 38: 435-445.
38. Jovanovic J, Takagi J, Choulier L, Abrescia NGA, Stuart DI, et al. (2007) alphavbeta6 is a novel receptor for human fibrillin-1. Comparative studies of molecular determinants underlying integrin-RGD affinity and specificity. J Biol Chem 282: 6743-6751.
39. Mariko B, Ghandour Z, Raveaud S, Quentin M, Usson Y, et al. (2010) Microfibrils and fibrillin-1 induce integrin-mediated signaling, proliferation and migration in human endothelial cells. Am J Physiol Cell Physiol.
40. Senior RM, Griffin GL, Mecham RP, Wrenn DS, Prasad KU, et al. (1984) Val-Gly-Val-Ala-Pro-Gly, a repeating peptide in elastin, is chemotactic for fibroblasts and monocytes. J Cell Biol 99: 870-874.
41. Hance KA, Tataria M, Ziporin SJ, Lee JK, Thompson RW, (2002) Monocyte chemotactic activity in human abdominal aortic aneurysms: role of elastin degradation peptides and the 67-kD cell surface elastin receptor. J Vasc Surg 35: 254-61.
42. Booms P, Pregla R, Ney A, Barthel F, Reinhardt DP, et al. (2005) RGD-containing fibrillin-1 fragments upregulate matrix metalloproteinase expression in cell culture: a potential factor in the pathogenesis of the Marfan syndrome. Hum Genet 116: 51-61.
43. Booms P, Ney A, Barthel F, Moroy G, Counsell D, et al. (2006) A fibrillin-1-fragment containing the elastin-binding-protein GxxPG consensus sequence upregulates matrix metalloproteinase-1: biochemical and computational analysis. J Mol Cell Cardiol 40: 234-246.
44. Guo G, Booms P, Halushka M, Dietz HC, Ney A, et al. (2006) Induction of macrophage chemotaxis by aortic extracts of the mgR Marfan mouse model and a GxxPG-containing fibrillin-1 fragment. Circulation 114: 1855-62.
45. Paepe AD, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE, (1996) Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 62: 417-426.
46. Loeys BL, Dietz HC, Braverman AC, Callewaert BL, Backer JD, et al. (2010) The revised Ghent nosology for the Marfan syndrome. J Med Genet 47: 476-485.
47. Aksamit RR, Falk W, Leonard EJ, (1981) Chemotaxis by mouse macrophage cell lines. J Immunol 126: 2194-2199.
48. Wei SM, Erdei J, Fulop TJ, Robert L, Jacob MP, (1993) Elastin peptide concentration in human serum: variation with antibodies and elastin peptides used for the enzyme-linked immunosorbent assay. J Immunol Methods 164: 175-87.
49. Hinek A, Wrenn DS, Mecham RP, Barondes SH, (1988) The elastin receptor: a galactoside-binding protein. Science 239: 1539-1541.
50. Pereira L, Lee SY, Gayraud B, Andrikopoulos K, Shapiro SD, et al. (1999) Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. Proc Natl Acad Sci U S A 96: 3819-3823.
51. Wrenn DS, Griffin GL, Senior RM, Mecham RP, (1986) Characterization of biologically active domains on elastin: identification of a monoclonal antibody to a cell recognition site. Biochemistry 25: 5172-5176.
52. Brassart B, Fuchs P, Huet E, Alix AJ, Wallach J, et al. (2001) Conformational dependence of collagenase (matrix metalloproteinase-1) up-regulation by elastin peptides in cultured fibroblasts. J Biol Chem 276: 5222-5227.
53. Schlatmann TJ, Becker AE, (1977) Histologic changes in the normal aging aorta: implications for dissecting aortic aneurysm. Am J Cardiol 39: 13-20.
54. Shinohara T, Suzuki K, Okada M, Shiigai M, Shimizu M, et al. (2003) Soluble elastin fragmentsin serum are elevated in acute aortic dissection. Arterioscler Thromb Vasc Biol 23: 1839-1844.
55. Dillon TJ, Walsh RL, Scicchitano R, Eckert B, Cleary EG, et al. (1992) Plasma elastin-derived peptide levels in normal adults, children, and emphysematous subjects. physiologic and computed tomographic scan correlates. Am Rev Respir Dis 146: 1143-1148.
56. Long MM, King VJ, Prasad KU, Urry DW, (1988) Chemotaxis of fibroblasts toward nonapeptide of elastin. Biochim Biophys Acta 968: 300-311.
57. Houghton AM, Quintero PA, Perkins DL, Kobayashi DK, Kelley DG, et al. (2006) Elastin fragments drive disease progression in a murine model of emphysema. J Clin Invest 116: 753-759.
58. Varga Z, Jacob MP, Robert L, Csongor J, Fulop T, (1997) Age-dependent changes of K-elastin stimulated effector functions of human phagocytic cells: relevance for atherogenesis. Exp Gerontol 32: 653-662.
59. Fulop T, Larbi A, Fortun A, Robert L, Khalil A, (2005) Elastin peptides induced oxidation of LDL by phagocytic cells. Pathol Biol (Paris) 53: 416-423.
60. Krettek A, Sukhova GK, Libby P, (2003) Elastogenesis in human arterial disease: a role for macrophages in disordered elastin synthesis. Arterioscler Thromb Vasc Biol 23: 582-587.
61. Milewicz DM, Guo DC, Tran-Fadulu V, Lafont AL, Papke CL, et al. (2008) Genetic basis of thoracic aortic aneurysms and dissections: focus on smooth muscle cell contractile dysfunction. Annu Rev Genomics Hum Genet 9: 283-302.